Piggybacking and IOL is a successful technique

Article

Piggybacking with the Add-On IOL is safe, efficient and reliable for correcting pseudophakic refractive errors.

Piggybacking with the Add-On IOL is safe, efficient and reliable for correcting pseudophakic refractive errors.

A team led by Dr B. Basarir, Beyoglu Eye Education and Research Hospital, Istanbul, Turkey, included 10 eyes of 10 patients with pseudophakic refractive errors. All patients were targeted to achieve a range of refraction between -0.50 to +0.50 D.

Preoperative and postoperative outcome measures included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell count (ECC), anterior chamber depth (ACD), the distance between intraocular lenses and contrast sensitivity measurements under mesopic, scotopic, and scotopic with glare conditions.

The mean preoperative and postoperative UDVA was 0.133±0.12 and 0.73±0.27, respectively. Mean preoperative and postoperative CDVA were 0.77±0.26 and 0.79±0.27, respectively.

The findings revealed the mean preoperative and postoperative ACD to be 3.87±0.91 mm vs. 3.58±1.05 mm, respectively. All patients achieved the target refractive range of -0.50 D to +0.50 D and no complications were recorded.

The abstract, recently published in the European Journal of Ophthalmology can be found here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.